8001 Background: c-Met-amplified NSCLC defines a subset of NSCLC that may be sensitive
to the small-molecule tyrosine kinase inhibitor crizotinib, approved multinationally for the …

… Lung cancer is a major cause of morbidity and mortality. In the United States, it is the leading
cause of cancer … survival rate for lung cancer is only 15%, among the lowest relative to other …

… Lung cancer is a major threat to human health. The 2018 global cancer statistics reported that
lung cancer … cell lung cancer (including squamous cell lung cancer, lung adenocarcinoma, …

… Immune checkpoint inhibitors (ICIs) are new therapeutic strategies for non-small cell lung
cancer (NSCLC). We aimed to quantitatively evaluate the efficacy and safety of ICIs in NSCLC. …

… efficacy with ALK inhibitors, including alectinib.3, 8 Here we report updated efficacy and safety
… 1, 2017) and an exploratory analysis of efficacy by EML4-ALK fusion variant. We discuss …

… In this study, we examined the efficacy and safety of a short-term treatment with … due to
primary lung cancer or metastatic cancer to the lungs. Efficacy and safety of levodropropizine and …

… In conclusion, these results support the efficacy and safety profile of bevacizumab-… lung
cancer therapies in this patient group. With greater inclusion of older patients in lung cancer trials…

We evaluated the safety, pharmacokinetic profile, pharmacodynamic effects, and antitumor
activity of abemaciclib, an orally bioavailable inhibitor of cyclin-dependent kinases (CDK) 4 …

… Lung cancer is the leading cause of cancer deaths worldwide. Approximately 400,000 new
cases of lung cancer are diagnosed every year in Europe; lung … cancers in men. Citation1 …

… of first-line (1L) therapy for advanced non-small cell cancer (NSCLC). The objective of this
study was to evaluate the relative efficacy, safety, and health-related quality of life (HRQoL) of …